These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38148017)

  • 1. Use of R-mini-CHP in combination with polatuzumab vedotin (pola-R-mini-CHP) as the primary treatment in ≥80-year-old cases with diffuse large B-cell lymphoma.
    Sekiguchi Y; Tsutsumi H; Gomyo A; Kudo M; Iizaki Y; Maseki N; Kawamura M; Kobayashi K; Nishimura Y; Kanda H; Nitta H; Noguchi M; Kobayashi H
    J Clin Exp Hematop; 2023; 63(4):262-265. PubMed ID: 38148017
    [No Abstract]   [Full Text] [Related]  

  • 2. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.
    Tilly H; Morschhauser F; Sehn LH; Friedberg JW; Trněný M; Sharman JP; Herbaux C; Burke JM; Matasar M; Rai S; Izutsu K; Mehta-Shah N; Oberic L; Chauchet A; Jurczak W; Song Y; Greil R; Mykhalska L; Bergua-Burgués JM; Cheung MC; Pinto A; Shin HJ; Hapgood G; Munhoz E; Abrisqueta P; Gau JP; Hirata J; Jiang Y; Yan M; Lee C; Flowers CR; Salles G
    N Engl J Med; 2022 Jan; 386(4):351-363. PubMed ID: 34904799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (pola-R-CHP) in previously untreated diffuse large B-cell lymphoma in Germany.
    Kambhampati S; Shumilov E; Saumoy M; Herrera AF; Tilly H; Lenz G; Thiruvengadam NR
    Br J Haematol; 2023 Aug; 202(4):771-775. PubMed ID: 37188351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma.
    Kambhampati S; Saumoy M; Schneider Y; Pak S; Budde LE; Mei MG; Siddiqi T; Popplewell LL; Wen YP; Zain J; Forman SJ; Kwak LW; Rosen ST; Danilov AV; Herrera AF; Thiruvengadam NR
    Blood; 2022 Dec; 140(25):2697-2708. PubMed ID: 35700381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. US cost-effectiveness analysis of polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma.
    Matasar M; Masaquel A; S Ho R; Launonen A; Ng CD; Wang R; Fox D; Hossain F; Li J; Burke JM
    J Med Econ; 2023; 26(1):1134-1144. PubMed ID: 37674384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.
    Tilly H; Morschhauser F; Bartlett NL; Mehta A; Salles G; Haioun C; Munoz J; Chen AI; Kolibaba K; Lu D; Yan M; Penuel E; Hirata J; Lee C; Sharman JP
    Lancet Oncol; 2019 Jul; 20(7):998-1010. PubMed ID: 31101489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of combination therapy of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone for previously untreated diffuse large B-cell lymphoma in Japan.
    Mizuoka T; Sakamaki H; Fuji S; Saito S; Murata T; Ohno S; Inubashiri N; Oshima T; Yamamoto K
    J Med Econ; 2023; 26(1):1122-1133. PubMed ID: 37656225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superiority of polatuzumab vedotin over other novel agents in previously untreated ABC-type diffuse large B-cell lymphoma: a network meta-analysis of 20 RCTs.
    Sheng Z; Li D; Chen B; Zhao C; Zhang W; Ding B; Wang L
    Ann Hematol; 2023 May; 102(5):1011-1017. PubMed ID: 36947214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial.
    Song Y; Tilly H; Rai S; Zhang H; Jin J; Goto H; Terui Y; Shin HJ; Kim WS; Cao J; Feng J; Eom HS; Kim TM; Tsai XC; Gau JP; Koh H; Zhang L; Song Y; Yang Y; Li W; Huang H; Ando K; Sharman JP; Sehn LH; Bu L; Wang X; Jiang Y; Hirata J; Lee C; Zhu J; Izutsu K
    Blood; 2023 Apr; 141(16):1971-1981. PubMed ID: 36626583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma.
    Shemesh CS; Agarwal P; Lu T; Lee C; Dere RC; Li X; Li C; Jin JY; Girish S; Miles D; Lu D
    Cancer Chemother Pharmacol; 2020 May; 85(5):831-842. PubMed ID: 32222808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pola-R-CHP for frontline therapy in DLBCL: Are we saving money by spending more?
    Vitolo U; Frascione PMM; Bonello F
    Br J Haematol; 2023 Aug; 202(4):731-733. PubMed ID: 37313856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of 5-year overall survival of diffuse large B-cell lymphoma on the pola-R-CHP regimen based on 2-year event-free survival and progression-free survival.
    Zhang WR; Liu X; Zhong QZ; Wu T; Yang Y; Chen B; Jing H; Tang Y; Jin J; Liu YP; Song YW; Fang H; Lu NN; Li N; Zhai YR; Zhang WW; Wang SL; Chen F; Yin L; Qi SN; Li YX
    Cancer Med; 2024 Jan; 13(1):e6899. PubMed ID: 38180169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
    Abrisqueta P; González-Barca E; Panizo C; Pérez JMA; Miall F; Bastos-Oreiro M; Triguero A; Banerjee L; McMillan A; Seymour E; Hirata J; de Guzman J; Sharma S; Jin HY; Musick L; Diefenbach C
    Lancet Haematol; 2024 Feb; 11(2):e136-e146. PubMed ID: 38190832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Sehn LH; Herrera AF; Flowers CR; Kamdar MK; McMillan A; Hertzberg M; Assouline S; Kim TM; Kim WS; Ozcan M; Hirata J; Penuel E; Paulson JN; Cheng J; Ku G; Matasar MJ
    J Clin Oncol; 2020 Jan; 38(2):155-165. PubMed ID: 31693429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma.
    Walji M; Assouline S
    Expert Rev Hematol; 2020 Sep; 13(9):933-942. PubMed ID: 32700586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of retreatment with polatuzumab vedotin in combination with rituximab in polatuzumab vedotin-resistant DLBCL models.
    Kawasaki N; Tomita M; Yamashita-Kashima Y; Yoshimura Y; Yoshiura S
    Leuk Lymphoma; 2023 Dec; 64(12):1938-1948. PubMed ID: 37548343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of statistical methods for extrapolating survival in previously untreated diffuse large B-cell lymphoma: results based on the POLARIX study.
    Ho RS; Launonen A
    J Med Econ; 2023; 26(1):1178-1189. PubMed ID: 37702406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: no ordinary subgroup analysis.
    Russler-Germain DA; Cliff ERS; Bartlett NL
    Blood; 2023 Dec; 142(25):2216-2219. PubMed ID: 37797275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma.
    Bourbon E; Salles G
    Expert Opin Investig Drugs; 2020 Oct; 29(10):1079-1088. PubMed ID: 32700972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma.
    Kawasaki N; Nishito Y; Yoshimura Y; Yoshiura S
    Br J Haematol; 2022 Oct; 199(2):245-255. PubMed ID: 35764309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.